Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23947855 | 1.00 | KDM4E (0.35) | KDM4EATML3MBTL1SIRT2SIRT1 | |
| SCHEMBL23947860 | 0.97 | KDM4E (0.37) | KDM4EATML3MBTL1SIRT2SIRT1 | |
| SCHEMBL24264103 | 0.96 | KDM4E (0.35) | KDM4EATML3MBTL1SIRT2SIRT1 | |
| SCHEMBL23947105 | 0.96 | KDM4E (0.35) | KDM4EATML3MBTL1SIRT2SIRT1 | |
| SCHEMBL24264025 | 0.96 | KDM4E (0.35) | KDM4EATML3MBTL1SIRT2SIRT1 | |
| SCHEMBL24264231 | 0.96 | KDM4E (0.33) | KDM4EATML3MBTL1SIRT2SIRT1 | |
| SCHEMBL23947234 | 0.95 | KDM4E (0.37) | KDM4EATML3MBTL1CHEK2MMP12 | |
| SCHEMBL24264232 | 0.94 | KDM4E (0.32) | KDM4EATML3MBTL1CHEK2CYP1A2 | |
| SCHEMBL23947233 | 0.94 | KDM4E (0.35) | KDM4EATML3MBTL1MMP12 | |
| SCHEMBL27441981 | 0.93 | KDM4E (0.35) | KDM4EATML3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11832517-B2 | Heterocyclic compound and organic light emitting device comprising same | LG CHEM, LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11832517-B2 | Heterocyclic compound and organic light emitting device comprising same | LG CHEM, LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20220059778-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220059778-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | CRY1, TRPC1, CYP1A1 | KDM4E 2387/4885ATM 3669/4885L3MBTL1 1631/4885 |
| US-11832517-B2 | Heterocyclic compound and organic light emitting device comprising same | CRY1, TRPC1, CYP1A1 | KDM4E 2387/4885ATM 3669/4885L3MBTL1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.